R&D as a share of revenue is one number; the addressable market that revenue draws from is another — and for targeted oncology, a diagnostic patent helps set the second. Foundation Medicine holds US12649952B2, "NTRK fusion molecules and uses thereof" (issued June 9, 2026). Its CPC tags — C12Q 1/6886 (cancer nucleic-acid detection), C07K 16/2827 (antibodies) — mark it as precision-oncology IP for detecting a specific actionable alteration.
On the fundamentals: a targeted cancer drug is only as big as the population a test can identify. NTRK-fusion-driven tumors are rare but treatable with TRK inhibitors — and finding those patients requires the kind of fusion-detection method this grant covers. The diagnostic IP and the therapeutic revenue are coupled: improve detection, and you enlarge the treatable population; restrict it behind exclusive diagnostic claims, and you shape who captures the value.
Why this belongs in an R&D ledger: companion-diagnostic economics show up in a therapeutics company's fundamentals as partnership revenue, co-development spend, and the market-size assumptions baked into guidance. When a drugmaker models the addressable market for a targeted agent, it is implicitly modeling the reach of the diagnostics that find patients — and the IP behind those diagnostics, like this Foundation Medicine grant, is part of that calculus.
What the grant does not settle: the prevalence of the alteration, reimbursement for the test, or whether competing detection methods read around the claims. A diagnostic grant is an exclusivity claim on a detection method, not a guarantee of test volume or a fixed market size. The economics depend on adoption and payer behavior, which live outside the patent.
The earnings-desk read: when you decode a targeted-oncology company's R&D spend and guidance, remember that the addressable market is gated by diagnostics, and the diagnostics are gated by IP. Foundation Medicine's NTRK grant is one piece of that gate. The drug's revenue ceiling and the diagnostic's patent are the same economic story, read from the test side.